THE ROLE OF RESISTIN, IL-1β, IL-6 AND CERULOPL ASMIN IN THE PATHOGENESIS OF NON-ALCOHOLIC FAT T Y LIVER DISE ASE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Keywords:type 2 diabetes mellitus, nonalcoholic fatty liver disease, resistin, interleukins, ceruloplasmin.
To determine the role of resistin, IL-1β, IL-6 and ceruloplasmin in the development of NAFLD and cardiovascular complications in patients with type 2 diabetes, 82 patients with type 2 diabetes with NAFLD were examined. All patients were divided into groups depending on the degree of liver damage: group 1 (stage of steatosis) — included 22 patients, group 2 (stage of steatohepatitis, NASH) — 40 patients, group 3 (stage of fibrosis) — 20 patients. The control group included 7 patients with type 2 diabetes without liver damage.
Based on the stusy results analysis, it can be stated that adipokin resistin should be considered as one of the factors in the pathogenesis of NAFLD in patients with type 2 diabetes, namely as a marker of inflammatory changes in the liver in this category of patients. Further development of the disease at the stage of fibrosis is characterized by a slight decrease in the serum resistin concentration, which may indicate a decrease in inflammatory processes against the background of the development of fibrotic changes. It is at the stage of fibrosis that resistin is unidirectionally correlated with some lipid fractions, which confirms its role in atherogenesis and in the risk of developing cardiovascular complications of diabetes. With the development of NAFLD in patients with type 2 diabetes, the level of pro-inflammatory interleukins IL-1β and IL-6 increases
already at the stage of NAS. It reflects inflammatory changes in the liver of these patients. Further insignificant increase in the content of interleukins IL-1β and IL-6 in the serum of patients may indicate the preservation of a high level of inflammation both at the stage of steatohepatitis and in the future, in the formation of fibrosis.
We found no significant differences between ceruloplasmin levels in patients with type 2 diabetes with various stages of NAFLD and in the absence of liver damage
Andrejeva JaO. Problemy bezperervnoi' medychnoi' osvity ta nauky 2018; 4(32): 39-44.
Gnacinska M, Malgorzewicz S, Lysiak-Szydlowska W, Sworczak K. Endocrynol Pol 2010; 61(1): 36-41.
Ragino JuI, Timoshenko NA, Chernjavskij AM, et al. Ros Kardiol Zhurn 2017; 5(145): 111-116.
Vashhenko VI, Vashhenko TN. Psihofarmakologija i biologicheskaja narkologija 2006; 6(3): 1254-1269.
Colica C, Abenavoli L. J Translat Int Medicine 2018;6(1): 52-53.
Abenavoli L, Peta V. Rev Recent Clin Trials 2014; 9: 134-140.
Adolph TE, Grander C, Grabherr F, Tilg H. Int J Mol Sci 2017; 18(8): 1649.
Shen C, Zhao CY, Wang W, et al. BMC Gastroenterol 2014; 14: 39.